Jeffrey W. Ubben
Jeffrey Ubben is a founder, the chief executive officer and the chief investment officer of ValueAct Capital, a San Francisco-based investment partnership with more than $6 billion in assets under management.
View Older Stories View More Recent Stories
-
Bloomberg's "The Year Ahead: 2016" to Feature Apple's Angela Ahrendts, Bank Of America's Brian Moynihan, Credit Suisse's Tidjane Thiam, Fashion Legend Diane von Furstenberg and More
-
ValueAct rallies Valeant investors as company fends off attack: source
-
Drugmaker Valeant raises detailed defense but doubts remain
-
Valeant Pharma (VRX) Adds ValueAct's Morfit as Director
-
Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors
-
Valeant slump poses big threat to small hedge funds
-
Valeant Pharma (VRX) to Hold Investor Conference Call on October 26
-
Valeant Pharma (VRX) Will Hold Investor Conf. Call on Oct. 26th
-
Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015
-
Valeant vows to refute 'phantom sales' allegations
-
AmEx profit misses estimates as costs rise, dollar hurts
-
Hedge Funds on Edge as Valeant Pharma (VRX) Sinks
-
Microsoft proposes election of new board members
-
Veterans Health Administration and Indian Health Service Become First Federal Agencies to Gain Interoperability via DirectExchange, Receive Accreditation From EHNAC-DirectTrust for HISPs' Securit
-
Form SC 13D/A BAKER HUGHES INC Filed by: VA Partners I, LLC
-
Form SC 13D/A TWENTY-FIRST CENTURY Filed by: VA Partners I, LLC
-
Twenty-First Century Fox nominates ValueAct CEO to board
-
UPDATE: 21st Century Fox (FOXA) Nominates ValueAct's Ubben for Board Seat
-
21st Century Fox Nominates Jeffrey W. Ubben for Election to Board of Directors
-
Democrats take aim at drug prices, prompting sharp drops in biotech stocks
-
AltX Adds Cowen Group to Team of Strategic Investors
-
Form 4 MICROSOFT CORP For: Sep 03 Filed by: ValueAct Capital Management, LLC
-
On Sale: Buy This Credit Card Processor Cheaper Than Ubben's ValueAct Capital
-
Valeant Pharma (VRX) Adds ValueAct's Hale as Director
-
Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors
-
ValueAct Capital Confirms New Stake in American Express (AXP) - 13F
-
Form 4 WILLIS GROUP HOLDINGS For: Aug 10 Filed by: VA Partners I, LLC
-
Fitch Upgrades Allison Transmission's IDR to 'BB'; Outlook Stable
-
Fitch Upgrades Allison Transmission (ALSN) to 'BB'; Notes Steadily Improving Credit Profile
-
Form 4 ADOBE SYSTEMS INC For: Jun 26 Filed by: VA Partners I, LLC
-
Form SC 13D/A WILLIS GROUP HOLDINGS Filed by: VA Partners I, LLC
-
Notable Mergers and Acquisitions 6/30: (CELG)/(JUNO) (WSH)/(TW) (CSCO) (GLW)
-
Willis Group (WSH), Towers Watson (TW) Enter ~$18B Merger Agreement
-
Willis Group and Towers Watson Announce Merger to Create Leading Global Advisory, Broking and Solutions Firm
-
Form SC 13D/A AGRIUM INC Filed by: VA Partners I, LLC
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: VA Partners I, LLC
-
Form 4 Valeant Pharmaceuticals For: Jun 10 Filed by: UBBEN JEFFREY W
-
Valeant Pharma (VRX) Active Early Amid ValueAct Stock Sale
-
ValueAct Sold 4.2M Valeant Pharma (VRX) Shares
-
ValueAct Capital Discloses Sale of Shares of Valeant Pharmaceuticals International, Inc.
-
Form SC 13D/A TWENTY-FIRST CENTURY Filed by: VA Partners I, LLC
-
Valeant Pharmaceuticals Announces 2015 Annual Meeting Results
-
ValueAct Capital Raises Stake in Twenty-First Century Fox (FOXA) to 5.5%
-
Form SC 13D TWENTY-FIRST CENTURY Filed by: VA Partners I, LLC
-
Form SC 13D/A Allison Transmission Filed by: VA Partners I, LLC
-
Allison Transmission adds Gregory Spivy to board of directors
-
IBM (IBM) Taps Investment Banks to Aid in Defending Against Activist Investors
-
Form SC 13D/A MSCI Inc. Filed by: VA Partners I, LLC
-
ValueAct Capital Shows New 5.1% Stake in Baker Hughes Inc (BHI)
-
Form SC 13D/A MSCI Inc. Filed by: VA Partners I, LLC

